Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

By B. Rini, S. Halabi, J. Rosenberg, W. Stadler, D. Vaena, S. Ou, L. Archer, J. Atkins, J. Picus, P. Czaykowski and 2 more. Journal of Clinical Oncology, 2008

829 citations recorded by the source corpus.

Subfields: Nephrology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/27bbdb38e76c18646f73da28fc4fea8f1758f545

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. J. Bellmunt
2. N. Ferrara
3. B. Rini
4. Rakesh K. Jain

In Surgery

1. B. Rini
2. Rakesh K. Jain

Citations in the corpus

• Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. (2010, background): “1%, respectively, stratified).(8,9) Differences in the patient populations of these trials do not allow direct comparisons with AVOREN.”
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial (2010, result): “The effects of PFS and RR in the treatment-naive subpopulation observed in this phase III trial are comparable to published data for sunitinib and bevacizumab (with IFN).(8,10,11) When this study was initiated in April 2006, limited access to the multikinase inhibitors sunitinib and sorafenib preclu”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “83) 1 [131] by gest on M ay 0, 2015 http://annofordjournals.”
• Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. (2010, methodology): “Dose modifications for toxicity were undertaken as previously described.(21) Bevacizumab was provided by the NCI Cancer Therapy Evaluation Program and was administered at a dose of 10 mg/kg actual body weight intravenously on days 1 and 15 of each 28-day cycle.”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Two Phase III studies, CALGB 90206 and AVOREN, found that the addition of bevacizumab to interferon-α2a (IFNα2a) significantly improved PFS 83,84 (TABLE 1) , supporting this combination as first-line treatment in patients with metastatic renal cell carcinoma.”
• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018, neutral): “Female 111 (26) 121 (29) 137 (25) 151 (28)”